Description
Odanacatib is an inhibitor of cathepsin K that displays anti-osteoporotic and anti-resorptive activities. Odanacatib protects bone against periapical infection and disease by preventing pathogenic infection, immune responses, and bone erosion. This compound is currently in clinical trials as a potential treatment for osteoporosis, where it inhibits bone resorption and increases bone mineral density.